16.2 Microbiome and immune interactions

Microbiome and Immune System Interactions

The human microbiome is the vast community of microorganisms that colonize virtually every surface of your body. These microbes don't just passively live on you; they actively shape how your immune system develops, responds to threats, and maintains tolerance to harmless antigens. Understanding these interactions is central to emerging immunobiology research because microbiome disruption is now linked to a growing list of immune-mediated diseases.

Definition and Role of the Microbiome

The microbiome encompasses bacteria, viruses, fungi, and protozoa that inhabit the human body. The largest and most studied populations reside in the gut, but significant communities also colonize the skin, oral cavity, respiratory tract, and urogenital tract. The gut alone harbors an estimated 38 trillion bacterial cells, roughly matching the number of human cells in the body.

The microbiome's influence on immune development is profound:

• Immune cell maturation: Commensal microbes provide signals that drive the maturation of both innate and adaptive immune cells. Germ-free mice, for example, show severely underdeveloped immune systems, highlighting how dependent immune maturation is on microbial colonization.
• Self vs. non-self discrimination: The immune system learns to tolerate beneficial commensals while remaining reactive to pathogens. This "education" happens largely in early life and depends on microbial exposure.
• Gut-associated lymphoid tissue (GALT) formation: Microbial signals promote the development of Peyer's patches, isolated lymphoid follicles, and mesenteric lymph nodes, which together form the largest immune organ in the body.
• Antimicrobial peptide production: Commensals stimulate epithelial cells to secrete defensins and cathelicidins, which kill or inhibit pathogenic microbes at mucosal surfaces.
• Epithelial barrier integrity: The microbiome strengthens tight junctions between epithelial cells, reinforcing the physical barrier that prevents microbial translocation into underlying tissue.

Microbiome's Influence on Immune Responses

Innate immune responses

Microbial components such as lipopolysaccharide (LPS) and peptidoglycan activate pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), on innate immune cells. This tonic stimulation keeps the innate immune system in a state of readiness without triggering overt inflammation.

• Commensal-derived signals stimulate innate lymphoid cells (ILCs), particularly ILC3s in the gut, which produce IL-22 to reinforce mucosal barrier function.
• The microbiome primes neutrophil function, improving their ability to clear pathogens systemically.
• Macrophage phagocytic capacity and cytokine production are enhanced by microbial metabolites, keeping baseline innate defenses active.

Adaptive immune responses

The microbiome has a direct hand in shaping adaptive immunity, particularly in the gut:

• T cell differentiation: Certain commensals drive specific T cell fates. For instance, Bacteroides fragilis polysaccharide A promotes regulatory T cell (Treg) induction, while segmented filamentous bacteria (SFB) promote Th17 cell development in the small intestine. The balance between these populations is critical for maintaining tolerance while retaining the ability to fight mucosal pathogens.
• B cell activation and IgA production: Commensal bacteria stimulate B cells in GALT to produce secretory IgA, which coats gut bacteria and prevents them from breaching the epithelial barrier. This is a non-inflammatory mechanism of immune surveillance.
• Dendritic cell modulation: Gut dendritic cells sample microbial antigens and present them in ways that generally favor tolerogenic responses to commensals, while preserving inflammatory responses to true pathogens.

Metabolite production

Microbial metabolism generates bioactive molecules that directly regulate immune cell function:

• Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate are produced by bacterial fermentation of dietary fiber. Butyrate is particularly important: it serves as the primary energy source for colonocytes, promotes Treg differentiation via histone deacetylase (HDAC) inhibition, and strengthens epithelial barrier function.
• Tryptophan metabolites, including indole derivatives, activate the aryl hydrocarbon receptor (AhR) on immune cells, influencing ILC3 and Th17 responses at mucosal surfaces.

Microbiome Dysbiosis and Therapeutic Applications

Microbiome Dysbiosis in Immune Disorders

Dysbiosis refers to a disruption in the composition or function of the microbial community, typically characterized by reduced diversity, loss of beneficial species, and/or expansion of pathobionts. Dysbiosis doesn't just correlate with immune disease; in many cases, animal models demonstrate that it can causally drive immune pathology.

Inflammatory bowel disease (IBD)

IBD (Crohn's disease and ulcerative colitis) is the most studied example of dysbiosis-driven immune dysfunction:

• Patients consistently show reduced microbial diversity compared to healthy controls.
• Pro-inflammatory bacteria like Enterobacteriaceae expand, while beneficial species like Faecalibacterium prausnitzii (a major butyrate producer) decline.
• Loss of SCFA-producing bacteria weakens the epithelial barrier, increasing intestinal permeability ("leaky gut").
• Microbial antigens that cross the compromised barrier trigger excessive immune activation in the lamina propria, perpetuating chronic inflammation.

Allergies and the hygiene hypothesis

• Reduced microbial diversity in early life, particularly in the gut, is associated with increased risk of allergic diseases. This supports the hygiene hypothesis, which proposes that insufficient microbial exposure during critical developmental windows skews the immune system toward Th2-dominant responses.
• In allergic individuals, the Th1/Th2 balance tips toward Th2, promoting IgE production and eosinophil recruitment.
• Decreased production of immunoregulatory metabolites (especially SCFAs) further weakens Treg-mediated suppression of allergic inflammation.

Other dysbiosis-associated disorders

• Asthma: Altered airway and gut microbiome composition in early life correlates with asthma development. Specific gut bacterial signatures in infancy can predict asthma risk.
• Atopic dermatitis: Skin dysbiosis, particularly Staphylococcus aureus overgrowth with loss of commensal diversity, drives skin barrier dysfunction and inflammation.
• Autoimmune diseases: Dysbiosis has been linked to type 1 diabetes (altered gut permeability and molecular mimicry) and multiple sclerosis (gut microbes influencing CNS-directed T cell responses). These connections are still being actively investigated, but animal models provide strong mechanistic support.

Therapeutic Potential of Microbiome Modulation

Restoring a healthy microbiome is now a major therapeutic goal. Several approaches are in various stages of development and clinical use:

• Probiotics introduce live beneficial bacteria (commonly Lactobacillus and Bifidobacterium species) to restore microbial balance. Evidence is strongest for preventing antibiotic-associated diarrhea and certain pediatric conditions, though strain-specific effects make generalizations difficult.
• Prebiotics are non-digestible substrates (e.g., inulin, fructooligosaccharides) that selectively feed beneficial bacteria, promoting their growth and metabolite production.
• Synbiotics combine probiotics and prebiotics in a single formulation, aiming for synergistic effects.

Fecal microbiota transplantation (FMT) transfers processed fecal material from a healthy donor to a patient's gut:

1. FMT is most established for recurrent Clostridioides difficile infection, where cure rates exceed 85-90%.
2. Clinical trials are exploring FMT for IBD, metabolic syndrome, and other immune-mediated conditions, with mixed but promising early results.
3. Standardized protocols and donor screening remain active areas of development.

Next-generation microbiome therapeutics go beyond traditional probiotics:

• Engineered bacteria are designed to deliver specific therapeutic molecules (e.g., anti-inflammatory cytokines or enzymes) directly to the gut mucosa.
• Bacteriophage therapy uses viruses that selectively infect and kill targeted pathogenic bacteria without disrupting the broader community.

Dietary interventions remain one of the most accessible ways to modulate the microbiome. High-fiber diets increase SCFA production, while Mediterranean-style diets are associated with greater microbial diversity and reduced inflammatory markers.

Personalized microbiome medicine is an emerging frontier. By profiling an individual's microbiome composition and function, clinicians may eventually tailor probiotic strains, dietary recommendations, and therapeutic interventions to each patient's specific microbial landscape. This approach is still largely in the research phase but represents a major direction for the field.